Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
136-482-Hyaluronoglucosaminidase PH20 (rHuPH20)[1] Hyaluronidase[3] Hyaluronidase ,
Hyaluronidase ,
Hyaluronidase 💬 		--[1] 65 💬
2Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20)[3] Daratumumab,
Hyaluronidase,
Hyaluronidase (human recombinant)		[4] Hyaluronidase ,
Hyaluronidase ,
Hyaluronidase ,
Daratumumab 💬 		[1] CD38 💬 [7] Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬[1] 28 💬
3Daratumumab coformulato con ialuronidasi umana ricombinante (rHuPH20)[1] Daratumumab[1] Daratumumab 💬 [1] CD38 💬 [7] Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬[1] 28 💬
4Recombinant Human Hyaluronidase (rHuPH20)[2] Hyaluronidase,
Hyaluronidase (human recombinant)		[3] Hyaluronidase ,
Hyaluronidase ,
Hyaluronidase 💬 		--[1] 65 💬
5Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)[2] Hyaluronidase,
Hyaluronidase (human recombinant)		[3] Hyaluronidase ,
Hyaluronidase ,
Hyaluronidase 💬 		--[1] 65 💬
6RHuPH20----[2] 13, 14 💬
7SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)----[1] 65 💬
8SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)----[1] 65 💬